Metabolic nuclear receptor signaling and the inflammatory acute phase response

Trends in Endocrinology and Metabolism

Volumn 22, Issue 8, 2011, Pages 333-343

  Venteclef, Nicolas ^a,b   Jakobsson, Tomas ^a   Steffensen, Knut R ^a   Treuter, Eckardt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS RECEPTOR; HIGH DENSITY LIPOPROTEIN; LIVER RECEPTOR HOMOLOG 1; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE;

ACUTE PHASE RESPONSE; ADIPOCYTE; ADIPOSE TISSUE; ATHEROSCLEROSIS; DRUG POTENCY; GENE EXPRESSION; HUMAN; INFLAMMATION; LIPID METABOLISM; LIVER CELL; MOLECULAR INTERACTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ACUTE-PHASE REACTION; ADIPOSE TISSUE; ANIMALS; HUMANS; LIPOPROTEINS; LIVER; ORPHAN NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 79960918745     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2011.04.004     Document Type: Review

References (83)

1. Rosenfeld M.G., et al. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006, 20:1405-1428.
2. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
3. Glass C.K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol. 2010, 10:365-376.
4. Hotamisligil G.S., Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat. Rev. Immunol. 2008, 8:923-934.
5. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 2010, 72:219-246.
6. Pascual G., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
7. Ghisletti S., et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell 2007, 25:57-70.
8. Huang W., et al. Coronin 2A mediates actin-dependent de-repression of inflammatory response genes. Nature 2011, 470:414-418.
9. Treuter E., Venteclef N. Transcriptional control of metabolic and inflammatory pathways by nuclear receptor SUMOylation. Biochim. Biophys Acta 2011, 10.1016/j.bbadis.2010.12.008.
10. Venteclef N., et al. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev. 2010, 24:381-395.
11. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med. 1999, 340:448-454.
12. Moshage H. Cytokines and the hepatic acute phase response. J. Pathol. 1997, 181:257-266.
13. Tillett W.S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of Pneumococcus. J. Exp. Med. 1930, 52:561-571.
14. Quaye I.K. Haptoglobin, inflammation and disease. Trans. R. Soc. Trop. Med. Hyg. 2008, 102:735-742.
15. Casas J.P., et al. C-reactive protein and coronary heart disease: a critical review. J. Intern. Med. 2008, 264:295-314.
16. Chiellini C., et al. Serum haptoglobin: a novel marker of adiposity in humans. J. Clin. Endocrinol. Metab. 2004, 89:2678-2683.
17. Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J. Clin. Invest. 2003, 111:1805-1812.
18. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
19. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008, 454:428-435.
20. Shi H., et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 2006, 116:3015-3025.
21. Fang C., et al. Hepatic expression of multiple acute phase proteins and down-regulation of nuclear receptors after acute endotoxin exposure. Biochem. Pharmacol. 2004, 67:1389-1397.
22. Blaschke F., et al. A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor. Circ. Res. 2006, 99:e88-99.
23. Wang Y.Y., et al. Liver X receptor agonist GW3965 dose-dependently regulates lps-mediated liver injury and modulates posttranscriptional TNF-alpha production and p38 mitogen-activated protein kinase activation in liver macrophages. Shock 2009, 32:548-553.
24. Venteclef N., Delerive P. Interleukin-1 receptor antagonist induction as an additional mechanism for liver receptor homolog-1 to negatively regulate the hepatic acute phase response. J. Biol. Chem. 2007, 282:4393-4399.
25. Venteclef N., et al. Liver receptor homolog 1 is a negative regulator of the hepatic acute-phase response. Mol. Cell. Biol. 2006, 26:6799-6807.
26. Gervois P., et al. Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor alpha agonists via inhibition of CCAAT box/enhancer-binding protein beta. J. Biol. Chem. 2001, 276:33471-33477.
27. Kleemann R., et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004, 103:4188-4194.
28. Mansouri R.M., et al. Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response. Endocrinology 2008, 149:3215-3223.
29. Stienstra R., et al. The Interleukin-1 receptor antagonist is a direct target gene of PPARalpha in liver. J. Hepatol. 2007, 46:869-877.
30. Li H., et al. SAA activates peroxisome proliferator-activated receptor gamma through extracellular-regulated kinase 1/2 and COX-2 expression in hepatocytes. Biochemistry 2010, 49:9508-9517.
31. Mahajan N., Dhawan V. In vitro modulation of peroxisome proliferator-activated receptor-gamma and its genes by C-reactive protein. Role of atorvastatin. Arch. Med. Res. 2010, 41:154-161.
32. Modica S., et al. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept Signal. 2011, 8:e005.
33. Zhang S., et al. Suppression of interleukin-6-induced C-reactive protein expression by FXR agonists. Biochem. Biophys. Res. Commun. 2009, 379:476-479.
34. Wang Y., et al. Haptoglobin, an inflammation-inducible plasma protein. Redox Rep. 2001, 6:379-385.
35. Hadoke P.W., et al. Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease. Br. J. Pharmacol. 2009, 156:689-712.
36. Zhao Y., et al. Association between serum amyloid A and obesity: a meta-analysis and systematic review. Inflamm. Res. 2010, 59:323-334.
37. Sjoholm K., et al. Association of serum amyloid A levels with adipocyte size and serum levels of adipokines: differences between men and women. Cytokine 2009, 48:260-266.
38. Poitou C., et al. Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 2005, 48:519-528.
39. Calabro P., et al. Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease?. Intern. Emerg. Med. 2009, 4:25-34.
40. Ouchi N., et al. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
41. Poitou C., et al. Role of serum amyloid a in adipocyte-macrophage cross talk and adipocyte cholesterol efflux. J. Clin. Endocrinol. Metab. 2009, 94:1810-1817.
42. Yang R.Z., et al. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006, 3:e287.
43. de Beer M.C., et al. Impact of serum amyloid A on high density lipoprotein composition and levels. J. Lipid Res. 2010, 51:3117-3125.
44. Song C., et al. Serum amyloid A induction of cytokines in monocytes/macrophages and lymphocytes. Atherosclerosis 2009, 207:374-383.
45. Siersbaek R., et al. PPARgamma in adipocyte differentiation and metabolism--novel insights from genome-wide studies. FEBS Lett. 2010, 584:3242-3249.
46. Vernochet C., et al. Mechanisms regulating repression of haptoglobin production by peroxisome proliferator-activated receptor-gamma ligands in adipocytes. Endocrinology 2010, 151:586-594.
47. Kolak M., et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 2007, 92:720-724.
48. Hartemann-Heurtier A., et al. Effects of bed-time insulin versus pioglitazone on abdominal fat accumulation, inflammation and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes Res. Clin. Pract. 2009, 86:37-43.
49. Choi J.H., et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010, 466:451-456.
50. Straus D.S., Glass C.K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 2007, 28:551-558.
51. Jahangiri A. High-density lipoprotein and the acute phase response. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:156-160.
52. Khovidhunkit W., et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 2004, 45:1169-1196.
53. Lu B., et al. Type II nuclear hormone receptors, coactivator, and target gene repression in adipose tissue in the acute-phase response. J. Lipid Res. 2006, 47:2179-2190.
54. Degoma E.M., Rader D.J. Novel HDL-directed pharmacotherapeutic strategies. Nat Rev Cardiol 2011, 8:266-277.
55. Jahangiri A., et al. HDL remodeling during the acute phase response. Arterioscler. Thromb. Vasc. Biol. 2009, 29:261-267.
56. King V.L., et al. A murine model of obesity with accelerated atherosclerosis. Obesity (Silver Spring) 2010, 18:35-41.
57. Tam S.P., et al. Acute-phase-HDL remodeling by heparan sulfate generates a novel lipoprotein with exceptional cholesterol efflux activity from macrophages. PLoS ONE 2008, 3:e3867.
58. Annema W., et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J. Lipid Res. 2010, 51:743-754.
59. Feingold K.R., Grunfeld C. The acute phase response inhibits reverse cholesterol transport. J. Lipid Res. 2010, 51:682-684.
60. McGillicuddy F.C., et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009, 119:1135-1145.
61. Banka C.L., et al. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J. Lipid Res. 1995, 36:1058-1065.
62. Cigliano L., et al. Haptoglobin binds the antiatherogenic protein apolipoprotein E - impairment of apolipoprotein E stimulation of both lecithin:cholesterol acyltransferase activity and cholesterol uptake by hepatocytes. FEBS J. 2009, 276:6158-6171.
63. Wang X., et al. C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:519-526.
64. Gordon S.M., et al. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol. Metab. 2010, 22:9-15.
65. Khera A.V., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 2011, 364:127-135.
66. Calkin A.C., Tontonoz P. Liver X receptor signaling pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1513-1518.
67. Molteni V., et al. N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta. J. Med. Chem. 2007, 50:4255-4259.
68. Zuercher W.J., et al. Discovery of tertiary sulfonamides as potent liver X receptor antagonists. J. Med. Chem. 2010, 53:3412-3416.
69. Yasuda T., et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler. Thromb. Vasc. Biol. 2010, 30:781-786.
70. Lo Sasso G., et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 2010, 12:187-193.
71. Marnell L., et al. C-reactive protein: ligands, receptors and role in inflammation. Clin. Immunol. 2005, 117:104-111.
72. Habersberger J., et al. C-reactive protein measurement and cardiovascular disease. Lancet 2010, 375:1078.
73. Elliott P., et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009, 302:37-48.
74. Xi L., et al. C-reactive protein impairs hepatic insulin sensitivity and insulin signaling in rats: role of mitogen-activated protein kinases. Hepatology 2011, 53:127-135.
75. Levy A.P., et al. Haptoglobin: basic and clinical aspects. Antioxid. Redox Signal. 2010, 12:293-304.
76. Zirlik A., et al. Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes. Thromb. Haemost. 2009, 101:1060-1069.
77. Hoo R.L., et al. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2777-2782.
78. Aso Y. Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front. Biosci. 2007, 12:2957-2966.
79. Devaraj S., et al. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107:398-404.
80. Fernandez-Marcos P.J., et al. Emerging actions of the nuclear receptor LRH-1 in the gut. Biochim. Biophys Acta. 2010, 10.1016/j.bbadis.2010.12.010.
81. Coste A., et al. LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:13098-13103.
82. Delerive P., et al. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 2001, 169:453-459.
83. Jakobsson T., et al. GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus. Mol. Cell 2009, 34:510-518.